Cargando…

Pleural effusion as a novel prognostic factor in metastatic thyroid carcinoma

OBJECTIVE: To identify novel prognostic risk factors and compare them with other known prognostic risk factors in follicular-cell-derived thyroid carcinoma (FDTC) with distant metastases. METHODS: A retrospective review was conducted of adult patients with metastatic FDTC seen at a tertiary care cen...

Descripción completa

Detalles Bibliográficos
Autores principales: Broome, David T, Gadre, Gauri B, Fayazzadeh, Ehsan, Bena, James F, Nasr, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487194/
https://www.ncbi.nlm.nih.gov/pubmed/32738128
http://dx.doi.org/10.1530/EC-20-0193
_version_ 1783581441870790656
author Broome, David T
Gadre, Gauri B
Fayazzadeh, Ehsan
Bena, James F
Nasr, Christian
author_facet Broome, David T
Gadre, Gauri B
Fayazzadeh, Ehsan
Bena, James F
Nasr, Christian
author_sort Broome, David T
collection PubMed
description OBJECTIVE: To identify novel prognostic risk factors and compare them with other known prognostic risk factors in follicular-cell-derived thyroid carcinoma (FDTC) with distant metastases. METHODS: A retrospective review was conducted of adult patients with metastatic FDTC seen at a tertiary care center between January 1990 and December 2010. A 15-year Kaplan–Meier survival estimate was created for overall survival (OS) and cancer-specific survival (CSS). Hazard ratios (HR) and P values from Cox proportional hazard models were used with a 95% CI. RESULTS: There were 143 patients (60.1% male, 39.9% female), of whom 104 (72.7%) patients had papillary, 30 (21.0%) had follicular, 5 (3.5%) had poorly differentiated, and 4 (2.8%) had Hürthle cell cancers. Median length of follow-up was 80.0 months (range 1.0–564.0). The 15-year mortality rate was 32.2% and cancer-specific mortality was 25.2%, with OS and CSS having the same risk factors. Lung was the most common site of metastases in 53 patients (37.1%), and patients with pleural effusions had significantly lower CSS (HR = 5.21, CI = 1.79–15.12). Additional risk factors for a decreased CSS included: older age upon diagnosis (>45 years, HR = 4.15, CI = 1.43–12.02), multiple metastatic locations (HR = 3.75, CI = 1.32–10.67), and incomplete/unknown tumor resection (HR = 2.35, CI = 1.18–4.67). CONCLUSION: This study is the first to demonstrate that pleural effusion is a poor prognostic sign in patients with FDTC with distant metastases and compare this risk with other accepted prognostic variables.
format Online
Article
Text
id pubmed-7487194
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Bioscientifica Ltd
record_format MEDLINE/PubMed
spelling pubmed-74871942020-09-16 Pleural effusion as a novel prognostic factor in metastatic thyroid carcinoma Broome, David T Gadre, Gauri B Fayazzadeh, Ehsan Bena, James F Nasr, Christian Endocr Connect Research OBJECTIVE: To identify novel prognostic risk factors and compare them with other known prognostic risk factors in follicular-cell-derived thyroid carcinoma (FDTC) with distant metastases. METHODS: A retrospective review was conducted of adult patients with metastatic FDTC seen at a tertiary care center between January 1990 and December 2010. A 15-year Kaplan–Meier survival estimate was created for overall survival (OS) and cancer-specific survival (CSS). Hazard ratios (HR) and P values from Cox proportional hazard models were used with a 95% CI. RESULTS: There were 143 patients (60.1% male, 39.9% female), of whom 104 (72.7%) patients had papillary, 30 (21.0%) had follicular, 5 (3.5%) had poorly differentiated, and 4 (2.8%) had Hürthle cell cancers. Median length of follow-up was 80.0 months (range 1.0–564.0). The 15-year mortality rate was 32.2% and cancer-specific mortality was 25.2%, with OS and CSS having the same risk factors. Lung was the most common site of metastases in 53 patients (37.1%), and patients with pleural effusions had significantly lower CSS (HR = 5.21, CI = 1.79–15.12). Additional risk factors for a decreased CSS included: older age upon diagnosis (>45 years, HR = 4.15, CI = 1.43–12.02), multiple metastatic locations (HR = 3.75, CI = 1.32–10.67), and incomplete/unknown tumor resection (HR = 2.35, CI = 1.18–4.67). CONCLUSION: This study is the first to demonstrate that pleural effusion is a poor prognostic sign in patients with FDTC with distant metastases and compare this risk with other accepted prognostic variables. Bioscientifica Ltd 2020-07-28 /pmc/articles/PMC7487194/ /pubmed/32738128 http://dx.doi.org/10.1530/EC-20-0193 Text en © 2020 The authors http://creativecommons.org/licenses/by-nc/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Research
Broome, David T
Gadre, Gauri B
Fayazzadeh, Ehsan
Bena, James F
Nasr, Christian
Pleural effusion as a novel prognostic factor in metastatic thyroid carcinoma
title Pleural effusion as a novel prognostic factor in metastatic thyroid carcinoma
title_full Pleural effusion as a novel prognostic factor in metastatic thyroid carcinoma
title_fullStr Pleural effusion as a novel prognostic factor in metastatic thyroid carcinoma
title_full_unstemmed Pleural effusion as a novel prognostic factor in metastatic thyroid carcinoma
title_short Pleural effusion as a novel prognostic factor in metastatic thyroid carcinoma
title_sort pleural effusion as a novel prognostic factor in metastatic thyroid carcinoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487194/
https://www.ncbi.nlm.nih.gov/pubmed/32738128
http://dx.doi.org/10.1530/EC-20-0193
work_keys_str_mv AT broomedavidt pleuraleffusionasanovelprognosticfactorinmetastaticthyroidcarcinoma
AT gadregaurib pleuraleffusionasanovelprognosticfactorinmetastaticthyroidcarcinoma
AT fayazzadehehsan pleuraleffusionasanovelprognosticfactorinmetastaticthyroidcarcinoma
AT benajamesf pleuraleffusionasanovelprognosticfactorinmetastaticthyroidcarcinoma
AT nasrchristian pleuraleffusionasanovelprognosticfactorinmetastaticthyroidcarcinoma